Merck and Moderna release detailed cancer vaccine data at ESMO
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall…
Moderna (MRNA)’s Melanoma Vaccine Win: Big Opportunity, Bigger Expectations
Moderna, Inc. (NASDAQ:MRNA) has delivered a major boost to its turnaround story. Its personalized mRNA cancer vaccine, Intismeran,…
Moderna Stock Surges on Stunning Cancer Update
This article first appeared on GuruFocus. Moderna (NASDAQ:MRNA) and Merck (NYSE:MRK) shares surged Wednesday after their personalized mRNA…
Moderna Shares Skyrocket 90% Toward Best Day Ever—Here’s Why
Topline Moderna’s stock soared by more than 90% as trading opened Wednesday, nearly doubling the biotech giant’s share…
Wall St set for higher open after retail earnings; Moderna soars
By Avinash P and Purvi Agarwal Aug 19 (Reuters) – The main U.S. stock indexes were on track…
New flu vaccine mFlusiva is approved for older people
WASHINGTON (AP) — The Food and Drug Administration has approved a new kind of flu vaccine for older…
Hantavirus cases spark surge in pharma, biotech stocks — here’s why
ILLUSTRATION of hantavirus testing concept with laboratory tubes containing cotton swabs and HANTAVIRUS labels photographed in front of…
FDA will consider Moderna’s mRNA flu vaccine after all
WASHINGTON (AP) — The Food and Drug Administration will consider whether to approve Moderna’s new flu vaccine after…
FDA reverses course, agrees to review Moderna’s flu vaccine
WASHINGTON — The Food and Drug Administration reversed course and told Moderna it would review its application for…
What the FDA’s Moderna rejection means for every vaccine maker
The Food and Drug Administration’s refusal to review Moderna’s flu vaccine this month has renewed fears that Trump…
Moderna’s president weighs in on FDA’s decision not to review its flu vaccine
Food and Drug Administration officials told Moderna in August that they would review its application for a new…
FDA refuses to review Moderna’s flu vaccine application
Helen Branswell covers issues broadly related to infectious diseases, including outbreaks, preparedness, research, and vaccine development. Follow her…